Bouygues: Disclosure of trading in own shares
REGULATED INFORMATION
Disclosure of trading in own shares
Paris, 15 June 2026
Disclosure of trading in own shares on 9, 10, 11 and 12 June 2026.
As part of the authorisation granted by the Annual General Meeting of 23 April 2026
I. Summary presentation
| Name of issuer | Identity code of issuer | Transaction date | Identity code of financial instrument | Total daily volume traded (number of shares) | Daily weighted average price of shares purchased | Market |
| BOUYGUES SA | 969500MOCLNQFNZN0D63 | 9 June 2026 | FR0000120503 | 120,000 | 49.3014 | XPAR |
| BOUYGUES SA | 969500MOCLNQFNZN0D63 | 10 June 2026 | FR0000120503 | 97,100 | 48.9537 | XPAR |
| BOUYGUES SA | 969500MOCLNQFNZN0D63 | 11 June 2026 | FR0000120503 | 48,000 | 49.4782 | XPAR |
| BOUYGUES SA | 969500MOCLNQFNZN0D63 | 12 June 2026 | FR0000120503 | 90,000 | 50.2661 | XPAR |
II. Detailed presentation
https://www.bouygues.com/app/uploads/2026/06/2026-06-15-declaration-agregee-et-detaillee-des-operations-realisees-par-BOUYGUES-sur-ses-propres-titres.xlsx
BOUYGUES SA
A Société Anonyme (public limited company) with a share capital of €385,323,631
Registered office: 32 Avenue Hoche, 75008 Paris, France
Registration No. 572 015 246 Paris – I.E. FR 29 572 015 246
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apeing Reaches Stage 5 of 33-Stage Token Presale as Project Reports More Than $108,000 Raised
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
- Tinghua Liquor’s Innovative Technology Receives Patent Recognition in Europe and the United States
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share